Vimarsana
Biggest News Aggregation in the World

Page 2 - Standard Protocol Items News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Standard Protocol Items. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Standard Protocol Items Today - Breaking & Trending Today

Guidelines for Reporting Outcomes in Trial Reports - Vimarsana News

Guidelines for Reporting Outcomes in Trial Reports

This report, the Consolidated Standards of Reporting Trials (CONSORT)–Outcomes 2022 extension, is a consensus statement on the standards for reporting outcomes

Guidelines for Reporting Outcomes in Trial Protocols - Vimarsana News

Guidelines for Reporting Outcomes in Trial Protocols

This report, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)–Outcomes 2022 extension, is a consensus statement on the standards

Structured reporting of study protocols - Vimarsana News

Structured reporting of study protocols

In this blog for Clinical Trials Day 2022, we reflect on the Trials journal Structured Study Protocol Template project since its launch in 2019.

Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research - Vimarsana News

Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research

These international, consensus-based, patient-reported outcomes (PRO)–specific guidelines aim to lay out the ethical considerations that researchers, research e

Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis - Vimarsana News

Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis

Benjamin Speich and colleagues investigate whether rates of trial completion and publication have increased over the past decade, the extent to which non-published trials can be identified in registries, and the association between reporting quality of protocols and premature discontinuation or non-publication of trials.

Source: plos.org